Do you expect continued movement away from one-stop-shop outsourcing toward deeper modality-specific expertise?

Patient apheresis heterogeneity from prior systemic therapy, collection settings, anticoagulants, timing, and transport/cryopreservation cannot be...

Alicia Castillo Holley hosts Jason Bock on her show. Curative Intent: on Engineering T-Cells, Patient Impact, and Chasing the Impossible. The...

By Jason Bock, Ph.D., CEO, and Duane Avant, CTO, CTMC Manufacturing autologous cell therapies requires close coordination with clinical staff, as...